Detalhe da pesquisa
1.
Identification of second-generation P2X3 antagonists for treatment of pain.
Bioorg Med Chem Lett
; 28(8): 1392-1396, 2018 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29548573
2.
Discovery of 5-aryl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-ones as positive allosteric modulators of metabotropic glutamate subtype-2 (mGlu2) receptors with efficacy in a preclinical model of psychosis.
Bioorg Med Chem Lett
; 26(4): 1260-4, 2016 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26810316
3.
In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters.
Drug Metab Dispos
; 41(3): 668-81, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23293300
4.
Discovery of 2,5-diarylnicotinamides as selective orexin-2 receptor antagonists (2-SORAs).
Bioorg Med Chem Lett
; 23(24): 6620-4, 2013 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24215892
5.
Conformational-Design-Driven Discovery of EZM0414: A Selective, Potent SETD2 Inhibitor for Clinical Studies.
ACS Med Chem Lett
; 13(7): 1137-1143, 2022 Jul 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-35859865
6.
Theoretical analysis of interplay of therapeutic protein drug and circulating soluble target: temporal profiles of 'free' and 'total' drug and target.
Pharm Res
; 28(10): 2447-57, 2011 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-21614635
7.
Pyridyl amides as potent inhibitors of T-type calcium channels.
Bioorg Med Chem Lett
; 21(6): 1692-6, 2011 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21316226
8.
Discovery of the Oxadiazine FRM-024: A Potent CNS-Penetrant Gamma Secretase Modulator.
J Med Chem
; 64(19): 14426-14447, 2021 10 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-34550687
9.
Discovery of a First-in-Class Inhibitor of the Histone Methyltransferase SETD2 Suitable for Preclinical Studies.
ACS Med Chem Lett
; 12(10): 1539-1545, 2021 Oct 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-34671445
10.
Use of in vivo animal models to assess pharmacokinetic drug-drug interactions.
Pharm Res
; 27(9): 1772-87, 2010 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-20428930
11.
Indazole derivatives as novel bradykinin B1 receptor antagonists.
Bioorg Med Chem Lett
; 20(23): 7011-4, 2010 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20971001
12.
Discovery and expanded SAR of 4,4-disubstituted quinazolin-2-ones as potent T-type calcium channel antagonists.
Bioorg Med Chem Lett
; 20(17): 5147-52, 2010 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20673719
13.
Discovery of 3,9-diazabicyclo[4.2.1]nonanes as potent dual orexin receptor antagonists with sleep-promoting activity in the rat.
Bioorg Med Chem Lett
; 20(14): 4201-5, 2010 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20610153
14.
3-Aryl-5-phenoxymethyl-1,3-oxazolidin-2-ones as positive allosteric modulators of mGluR2 for the treatment of schizophrenia: Hit-to-lead efforts.
Bioorg Med Chem Lett
; 20(10): 3129-33, 2010 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20409708
15.
Discovery of MK-8719, a Potent O-GlcNAcase Inhibitor as a Potential Treatment for Tauopathies.
J Med Chem
; 62(22): 10062-10097, 2019 11 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-31487175
16.
CYP2C75-involved autoinduction of metabolism in rhesus monkeys of methyl 3-chloro-3'-fluoro-4'-{(1R)-1-[({1-[(trifluoroacetyl)amino]cyclopropyl}carbonyl)amino]ethyl}-1,1'-biphenyl-2-carboxylate (MK-0686), a bradykinin B1 receptor antagonist.
J Pharmacol Exp Ther
; 325(3): 935-46, 2008 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-18310472
17.
A new class of bradykinin B1 receptor antagonists with high oral bioavailability and minimal PXR activity.
Bioorg Med Chem Lett
; 18(2): 682-7, 2008 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18240388
18.
Bradykinin B1 receptor antagonists: an alpha-hydroxy amide with an improved metabolism profile.
Bioorg Med Chem Lett
; 18(18): 5107-10, 2008 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18722115
19.
Alpha-hydroxy amides as a novel class of bradykinin B1 selective antagonists.
Bioorg Med Chem Lett
; 18(2): 716-20, 2008 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18061443
20.
Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferation.
PLoS One
; 13(6): e0197372, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29856759